PLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Protalix Biotherapeutics Inc (PLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, neutral trading sentiment, and absence of significant catalysts suggest that holding off on investment is prudent until more favorable conditions arise.
The stock shows mixed technical signals. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative and expanding downward (-0.0151), and RSI is neutral at 55.268. The pre-market price is up 5.32% at $3.17, trading above key resistance levels (R1: $3.151), but this may not indicate a sustainable trend.
Bullish moving averages and a slight pre-market price increase of 5.32%.
Declining financial performance in Q3 2025, with revenue (-0.60% YoY), net income (-27.22% YoY), and EPS (-25.00% YoY) all dropping. Analysts have lowered price targets recently, and there are no significant news or event-driven catalysts.
The company's Q3 2025 financials show a decline in revenue ($17.85M, -0.60% YoY), net income ($2.36M, -27.22% YoY), and EPS ($0.03, -25.00% YoY). Gross margin remained flat at 53.37%.
Recent analyst actions are neutral to bearish. Morgan Stanley and JPMorgan have both lowered price targets on the stock, with current targets at EUR 21 and EUR 18, respectively, and maintain neutral ratings.
